Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC Patients With T790M”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Not applicableStudy completedNCT02991274
What this trial is testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Who this might be right for
Locally Advanced or Metastatic EGFR(+) NSCLC Patients
AstraZeneca 897
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Early research (Phase 1)Ended earlyNCT02448251
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
ACEA Therapeutics, Inc. 28
Not applicableStudy completedNCT04031898
What this trial is testing

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

Who this might be right for
Lung Cancer
AstraZeneca 896
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Not applicableStudy completedNCT02777567
What this trial is testing

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Ended earlyNCT03452592
What this trial is testing

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Who this might be right for
Advanced NSCLC Patients With T790M
Allist Pharmaceuticals, Inc. 220
Testing effectiveness (Phase 2)Study completedNCT02108964
What this trial is testing

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Who this might be right for
Advanced Non-small Cell Lung Cancer
Novartis Pharmaceuticals 225
Testing effectiveness (Phase 2)Study completedNCT03513666
What this trial is testing

Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT02841579
What this trial is testing

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Who this might be right for
Non-Small Cell Lung Cancer
MedSIR 22
Early research (Phase 1)Study completedNCT02789345
What this trial is testing

Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Eli Lilly and Company 29
Testing effectiveness (Phase 2)UnknownNCT02330367
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 368
Testing effectiveness (Phase 2)UnknownNCT02811354
What this trial is testing

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Who this might be right for
Carcinoma, Non-Small-Cell Lung
National University Hospital, Singapore 108
Testing effectiveness (Phase 2)Study completedNCT03386955
What this trial is testing

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Beta Pharma Shanghai 215
Testing effectiveness (Phase 2)Ended earlyNCT02454842
What this trial is testing

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Rain Oncology Inc 21
Not applicableNo Longer AvailableNCT02451852
What this trial is testing

AZD9291 US Expanded Access Program

Who this might be right for
EGFR T790M Mutation Positive NSCLC
AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Next Page